Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 1 (January)

1. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
   Cancer Res, 69(1): 349-57. [Abstract] [Full-text]
2. The origins of breast cancer prognostic gene expression profiles.
   Cancer Res, 69(1): 310-8. [Abstract] [Full-text]
3. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation.
   Cancer Res, 69(1): 282-91. [Abstract] [Full-text]
4. Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer.
   Cancer Res, 69(1): 128-36. [Abstract] [Full-text]
5. GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells.
   Cancer Res, 69(1): 23-6. [Abstract] [Full-text]
6. Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer.
   Am J Pathol, 174(1): 297-308. [Abstract] [Full-text]
7. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method.
   J Med Chem, 52(1): 126-33. [Abstract] [Full-text]
8. Comparative effects of natural and synthetic diallyl disulfide on apoptosis of human breast-cancer MCF-7 cells.
   Biotechnol Appl Biochem, 52: 113-9. [Abstract] [Full-text]
9. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study.
   Am J Obstet Gynecol, 200(1): 72.e1-7. [Abstract] [Full-text]
10. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines.
    Proteomics, 9(1): 182-93. [Abstract] [Full-text]
11. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
    Am J Obstet Gynecol, 200(1): 80.e1-7. [Abstract] [Full-text]
12. Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study.
    Am J Obstet Gynecol, 200(1): 63.e1-5. [Abstract] [Full-text]
13. Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women.
    J Med Genet, 46(1): 32-9. [Abstract] [Full-text]
14. The surgical margin status after breast-conserving surgery: discussion of an open issue.
    Breast Cancer Res Treat, 113(2): 397-402. [Abstract] [Full-text]
15. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Breast Cancer Res Treat, 113(2): 357-70. [Abstract] [Full-text]
16. BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer.
    Breast Cancer Res Treat, 113(2): 393-5. [Abstract] [Full-text]
17. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Breast Cancer Res Treat, 113(2): 403-7. [Abstract] [Full-text]
18. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Breast Cancer Res Treat, 113(2): 275-83. [Abstract] [Full-text]
19. Germline RAP80 mutations and susceptibility to breast cancer.
    Breast Cancer Res Treat, 113(2): 377-81. [Abstract] [Full-text]
20. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
    Breast Cancer Res Treat, 113(2): 315-20. [Abstract] [Full-text]
21. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Breast Cancer Res Treat, 113(2): 253-60. [Abstract] [Full-text]
22. Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women.
    Breast Cancer Res Treat, 113(2): 383-91. [Abstract] [Full-text]
23. Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
    Breast Cancer Res Treat, 113(2): 285-91. [Abstract] [Full-text]
24. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
    Breast Cancer Res Treat, 113(2): 321-6. [Abstract] [Full-text]
25. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis.
    Breast Cancer Res Treat, 113(2): 239-49. [Abstract] [Full-text]
26. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications.
    Breast Cancer Res Treat, 113(2): 261-73. [Abstract] [Full-text]
27. Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
    Breast Cancer Res Treat, 113(2): 307-13. [Abstract] [Full-text]
28. Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer.
    Breast Cancer Res Treat, 113(2): 339-55. [Abstract] [Full-text]
29. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Breast Cancer Res Treat, 113(2): 231-7. [Abstract] [Full-text]
30. HER-2/neu expression in primary and metastatic breast cancer.
    Breast Cancer Res Treat, 113(2): 301-6. [Abstract] [Full-text]
31. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Breast Cancer Res Treat, 113(2): 293-9. [Abstract] [Full-text]
32. Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.
    Breast Cancer Res Treat, 113(2): 371-6. [Abstract] [Full-text]
33. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.
    Breast Cancer Res Treat, 113(2): 217-30. [Abstract] [Full-text]
34. Donor-derived breast cancer in a bone marrow transplantation recipient.
    Breast Cancer Res Treat, 113(2): 211-3. [Abstract] [Full-text]
35. Breaking bad news in the breast imaging setting.
    Acad Radiol, 16(2): 130-5. [Abstract] [Full-text]
36. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.
    J Natl Cancer Inst, 101(1): 61-6. [Abstract] [Full-text]
37. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.
    J Natl Cancer Inst, 101(1): 48-60. [Abstract] [Full-text]
38. BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.
    Br J Cancer, 100(1): 123-33. [Abstract] [Full-text]
39. Rising incidence of breast cancer among female cancer survivors: implications for surveillance.
    Br J Cancer, 100(1): 77-81. [Abstract] [Full-text]
40. Erythrocyte fatty acids and risk of proliferative and nonproliferative fibrocystic disease in women in Shanghai, China.
    Am J Clin Nutr, 89(1): 265-76. [Abstract] [Full-text]
41. Dietary carbohydrates, fiber, and breast cancer risk in Chinese women.
    Am J Clin Nutr, 89(1): 283-9. [Abstract] [Full-text]
42. Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women.
    Am J Clin Nutr, 89(1): 277-82. [Abstract] [Full-text]
43. Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment.
    Br J Cancer, 100(1): 160-6. [Abstract] [Full-text]
44. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer.
    Cancer Immunol Immunother, 58(3): 441-7. [Abstract] [Full-text]
45. Importance of routine cavity sampling in breast conservation surgery.
    Br J Surg, 96(1): 47-53. [Abstract] [Full-text]
46. Impact on regional recurrence and survival of axillary surgery in women with node-negative primary breast cancer.
    Br J Surg, 96(1): 40-6. [Abstract] [Full-text]
47. Nek2 as a novel molecular target for the treatment of breast carcinoma.
    Cancer Sci, 100(1): 111-6. [Abstract] [Full-text]
48. Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis.
    Cancer Sci, 100(1): 88-94. [Abstract] [Full-text]
49. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
    Nat Med, 15(1): 68-74. [Abstract] [Full-text]
50. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
    J Clin Oncol, 27(2): 227-34. [Abstract] [Full-text]
51. Ductal carcinoma in situ: state of the science and roadmap to advance the field.
    J Clin Oncol, 27(2): 279-88. [Abstract] [Full-text]
52. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
    J Clin Oncol, 27(2): 214-9. [Abstract] [Full-text]
53. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
    J Clin Oncol, 27(2): 220-6. [Abstract] [Full-text]
54. The metastatic capacity of multifocal breast carcinomas: extensive tumors versus tumors of limited extent.
    Hum Pathol, 40(2): 199-205. [Abstract] [Full-text]
55. Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer.
    Hum Pathol, 40(2): 156-65. [Abstract] [Full-text]
56. Practical application of contrast-enhanced magnetic resonance mammography [CE-MRM] by an algorithm combining morphological and enhancement patterns.
    Comput Med Imaging Graph, 33(2): 83-90. [Abstract] [Full-text]
57. Influence of estrogen plus testosterone supplementation on breast cancer.
    Arch Intern Med, 169(1): 41-6. [Abstract] [Full-text]
58. Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases.
    Am J Clin Pathol, 131(2): 228-42. [Abstract] [Full-text]
59. Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.
    Cell Prolif, 42(1): 38-48. [Abstract] [Full-text]
60. Alveolar soft part sarcoma presenting as a breast mass in a 13-year-old female.
    Diagn Cytopathol, 37(2): 122-4. [Abstract] [Full-text]
61. Current utilization of breast FNA in a cytology practice.
    Diagn Cytopathol, 37(2): 140-2. [Abstract] [Full-text]
62. Bim is reversibly phosphorylated but plays a limited role in paclitaxel cytotoxicity of breast cancer cell lines.
    Biochem Biophys Res Commun, 379(1): 145-50. [Abstract] [Full-text]
63. Radiotherapy timing in 4,820 patients with breast cancer: university of florence experience.
    Int J Radiat Oncol Biol Phys, 73(2): 365-9. [Abstract] [Full-text]
64. 3D ultrasound can contribute to planning CT to define the target for partial breast radiotherapy.
    Int J Radiat Oncol Biol Phys, 73(2): 375-83. [Abstract] [Full-text]
65. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Int J Radiat Oncol Biol Phys, 73(2): 357-64. [Abstract] [Full-text]
66. Effects of variable placement of superior tangential/supraclavicular match line on dosimetric coverage of level III axilla/axillary apex in patients treated with breast and supraclavicular radiotherapy.
    Int J Radiat Oncol Biol Phys, 73(2): 370-4. [Abstract] [Full-text]
67. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
    Cancer Res, 69(2): 663-71. [Abstract] [Full-text]
68. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
    Cancer Res, 69(2): 565-72. [Abstract] [Full-text]
69. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis.
    Cancer Res, 69(2): 501-9. [Abstract] [Full-text]
70. Overexpression of RhoA induces preneoplastic transformation of primary mammary epithelial cells.
    Cancer Res, 69(2): 483-91. [Abstract] [Full-text]
71. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells.
    Cancer Lett, 274(2): 327-30. [Abstract] [Full-text]
72. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles.
    Cancer Lett, 274(2): 319-26. [Abstract] [Full-text]
73. Dietary pattern influences breast cancer prognosis in women without hot flashes: the women's healthy eating and living trial.
    J Clin Oncol, 27(3): 352-9. [Abstract] [Full-text]
74. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms.
    J Clin Oncol, 27(3): 390-7. [Abstract] [Full-text]
75. Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for neoadjuvant chemotherapy.
    Gynecol Oncol, 112(2): 400-4. [Abstract] [Full-text]
76. Folate and one-carbon metabolism nutrients from supplements and diet in relation to breast cancer risk.
    Am J Clin Nutr, 89(2): 624-33. [Abstract] [Full-text]
77. Drinking green tea modestly reduces breast cancer risk.
    J Nutr, 139(2): 310-6. [Abstract] [Full-text]
78. Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast.
    J Pathol, 217(3): 380-8. [Abstract] [Full-text]
79. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.
    J Pathol, 217(3): 372-9. [Abstract] [Full-text]
80. Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis.
    Int J Cancer, 124(6): 1366-71. [Abstract] [Full-text]
81. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Int J Cancer, 124(6): 1457-62. [Abstract] [Full-text]
82. How different are luminal A and basal breast cancers?
    Int J Cancer, 124(6): 1338-48. [Abstract] [Full-text]
83. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women.
    Int J Cancer, 124(6): 1404-8. [Abstract] [Full-text]
84. Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
    Breast Cancer Res Treat, 113(3): 467-77. [Abstract] [Full-text]
85. Life-threatening interstitial lung disease associated with trastuzumab: case report.
    Breast Cancer Res Treat, 113(3): 609-12. [Abstract] [Full-text]
86. A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk.
    Breast Cancer Res Treat, 113(3): 585-94. [Abstract] [Full-text]
87. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
    Breast Cancer Res Treat, 113(3): 457-66. [Abstract] [Full-text]
88. Validation of the Tenon breast cancer score for predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis: a prospective multicenter study.
    Breast Cancer Res Treat, 113(3): 537-43. [Abstract] [Full-text]
89. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
    Breast Cancer Res Treat, 113(3): 491-9. [Abstract] [Full-text]
90. Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer.
    Breast Cancer Res Treat, 113(3): 519-28. [Abstract] [Full-text]
91. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study.
    Breast Cancer Res Treat, 113(3): 567-76. [Abstract] [Full-text]
92. Conservative surgery in patients with multifocal/multicentric breast cancer.
    Breast Cancer Res Treat, 113(3): 577-83. [Abstract] [Full-text]
93. Increased racial differences on breast cancer care and survival in America: historical evidence consistent with a health insurance hypothesis, 1975-2001.
    Breast Cancer Res Treat, 113(3): 595-600. [Abstract] [Full-text]
94. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
    Breast Cancer Res Treat, 113(3): 443-56. [Abstract] [Full-text]
95. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Breast Cancer Res Treat, 113(3): 529-35. [Abstract] [Full-text]
96. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Breast Cancer Res Treat, 113(3): 509-17. [Abstract] [Full-text]
97. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.
    Breast Cancer Res Treat, 113(3): 501-7. [Abstract] [Full-text]
98. Patho-biological aspects of basal-like breast cancer.
    Breast Cancer Res Treat, 113(3): 411-22. [Abstract] [Full-text]
99. Receipt of adjuvant systemic therapy among patients with high-risk breast cancer detected by mammography screening.
    Breast Cancer Res Treat, 113(3): 559-66. [Abstract] [Full-text]
100. Multiparity and the risk of premenopausal breast cancer: different effects across ethnic groups in Singapore.
     Breast Cancer Res Treat, 113(3): 553-8. [Abstract] [Full-text]
101. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes.
     Breast Cancer Res Treat, 113(3): 435-41. [Abstract] [Full-text]
102. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
     Breast Cancer Res Treat, 113(3): 479-90. [Abstract] [Full-text]
103. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
     Breast Cancer Res Treat, 113(3): 545-51. [Abstract] [Full-text]
104. Surveying germline genomic landscape of breast cancer.
     Breast Cancer Res Treat, 113(3): 601-3. [Abstract] [Full-text]
105. Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells.
     Breast Cancer Res Treat, 113(3): 423-34. [Abstract] [Full-text]
106. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
     J Natl Cancer Inst, 101(2): 80-7. [Abstract] [Full-text]
107. Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients.
     Jpn J Clin Oncol, 39(2): 97-104. [Abstract] [Full-text]
108. Breast imaging fellowships in the United States: who, what, and where?
     AJR Am J Roentgenol, 192(2): 403-7. [Abstract] [Full-text]
109. Decreased mammography utilization in the United States: why and how can we reverse the trend?
     AJR Am J Roentgenol, 192(2): 400-2. [Abstract] [Full-text]
110. Tailored supplemental screening for breast cancer: what now and what next?
     AJR Am J Roentgenol, 192(2): 390-9. [Abstract] [Full-text]
111. Image registration for detection and quantification of change on digital tomosynthesis mammographic volumes.
     AJR Am J Roentgenol, 192(2): 384-7. [Abstract] [Full-text]
112. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging.
     AJR Am J Roentgenol, 192(2): 379-83. [Abstract] [Full-text]
113. Workforce shortages in breast imaging: impact on mammography utilization.
     AJR Am J Roentgenol, 192(2): 370-8. [Abstract] [Full-text]
114. Radiologists' performance and their enjoyment of interpreting screening mammograms.
     AJR Am J Roentgenol, 192(2): 361-9. [Abstract] [Full-text]
115. Mammography use from 2000 to 2006: state-level trends with corresponding breast cancer incidence rates.
     AJR Am J Roentgenol, 192(2): 352-60. [Abstract] [Full-text]
116. False-negative diagnoses at stereotactic vacuum-assisted needle breast biopsy: long-term follow-up of 1,280 lesions and review of the literature.
     AJR Am J Roentgenol, 192(2): 341-51. [Abstract] [Full-text]
117. Detection of breast cancer with full-field digital mammography and computer-aided detection.
     AJR Am J Roentgenol, 192(2): 337-40. [Abstract] [Full-text]
118. Predictors of radiologists' perceived risk of malpractice lawsuits in breast imaging.
     AJR Am J Roentgenol, 192(2): 327-33. [Abstract] [Full-text]
119. Histogenesis of metaplastic breast carcinoma and axillary nodal metastases.
     Pathol Int, 59(2): 116-20. [Abstract] [Full-text]
120. Primary osteosarcoma of the breast.
     Pathol Int, 59(2): 111-5. [Abstract] [Full-text]
121. Pleomorphic carcinoma with osteoclastic giant cells of the breast: immunohistochemical differentiation between coexisting neoplastic and reactive giant cells.
     Pathol Int, 59(2): 91-7. [Abstract] [Full-text]
122. Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness.
     Biochem Biophys Res Commun, 379(2): 304-8. [Abstract] [Full-text]
123. Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years.
     Eur J Surg Oncol, 35(2): 159-63. [Abstract] [Full-text]
124. Partial breast irradiation with interstitial high-dose-rate brachytherapy in early breast cancer: results of a phase II prospective study.
     Eur J Surg Oncol, 35(2): 144-50. [Abstract] [Full-text]
125. Pregnancy associated breast cancer.
     Eur J Surg Oncol, 35(2): 215-8. [Abstract] [Full-text]
126. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.
     Eur J Surg Oncol, 35(2): 113-22. [Abstract] [Full-text]
127. Improvements in breast cancer survival over time, related to adjuvant treatment and node status.
     Eur J Surg Oncol, 35(2): 151-5. [Abstract] [Full-text]
128. Follow-up of benign screen-detected breast lesions with suspicious preoperative needle biopsies.
     Eur J Surg Oncol, 35(2): 156-8. [Abstract] [Full-text]
129. Evaluation of group genetic counseling for hereditary breast and ovarian cancer.
     J Genet Couns, 18(1): 87-100. [Abstract] [Full-text]
130. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
     Oncogene, 28(3): 461-8. [Abstract] [Full-text]
131. Do 'basal-like' breast cancers really exist?
     Nat Rev Cancer, 9(2): 128-34. [Abstract] [Full-text]
132. The medical decision-making process and the family: the case of breast cancer patients and their husbands.
     Bioethics, 23(3): 183-92. [Abstract] [Full-text]
133. Adherence to quality indicators and survival in patients with breast cancer.
     Med Care, 47(2): 217-25. [Abstract] [Full-text]
134. Residual disease after re-excision lumpectomy for close margins.
     J Surg Oncol, 99(2): 99-103. [Abstract] [Full-text]
135. An investigation of microRNAs mapping to breast cancer related genomic gain and loss regions.
     Cancer Genet Cytogenet, 189(1): 15-23. [Abstract] [Full-text]
136. The presence of micropapillary features and retraction artifact in core needle biopsy material predicts lymph node metastasis in breast carcinoma.
     Am J Surg Pathol, 33(2): 202-10. [Abstract] [Full-text]
137. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.
     Am J Surg Pathol, 33(2): 163-75. [Abstract] [Full-text]
138. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
     Am J Surg Pathol, 33(2): 256-63. [Abstract] [Full-text]
139. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
     Am J Surg Pathol, 33(2): 227-32. [Abstract] [Full-text]
140. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
     Bone, 44(2): 380-6. [Abstract] [Full-text]
141. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
     Eur J Endocrinol, 160(2): 215-25. [Abstract] [Full-text]
142. Hereditary breast cancer syndromes and clinical implications.
     J Plast Reconstr Aesthet Surg, 62(2): 181-9. [Abstract] [Full-text]
143. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
     BMC Cancer, 9: 20. [Abstract] [Full-text]
144. HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection.
     BMC Cancer, 9: 4. [Abstract] [Full-text]
145. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II.
     Arch Intern Med, 169(2): 115-21; discussion 121. [Abstract] [Full-text]
146. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer.
     Br J Surg, 96(2): 166-70. [Abstract] [Full-text]
147. No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women.
     Breast Cancer Res Treat, 114(1): 137-45. [Abstract] [Full-text]
148. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.
     Breast Cancer Res Treat, 114(1): 127-35. [Abstract] [Full-text]
149. Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology.
     Breast Cancer Res Treat, 114(1): 121-6. [Abstract] [Full-text]
150. The effect of thrombospondin-1 on breast cancer metastasis.
     Breast Cancer Res Treat, 114(1): 85-96. [Abstract] [Full-text]
151. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors.
     Breast Cancer Res Treat, 114(1): 155-67. [Abstract] [Full-text]
152. Mammary tumor development from T47-D human breast cancer cells in obese ovariectomized mice with and without estradiol supplements.
     Breast Cancer Res Treat, 114(1): 71-83. [Abstract] [Full-text]
153. Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy.
     Breast Cancer Res Treat, 114(1): 179-87. [Abstract] [Full-text]
154. Lifestyle changes and breast cancer prognosis: a review.
     Breast Cancer Res Treat, 114(1): 13-22. [Abstract] [Full-text]
155. The Women's Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem.
     Breast Cancer Res Treat, 114(1): 1-6. [Abstract] [Full-text]
156. Low frequency of human papillomavirus DNA in breast cancer tissue.
     Breast Cancer Res Treat, 114(1): 189-94. [Abstract] [Full-text]
157. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.
     Breast Cancer Res Treat, 114(1): 39-45. [Abstract] [Full-text]
158. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.
     Breast Cancer Res Treat, 114(1): 47-62. [Abstract] [Full-text]
159. Breast-feeding after breast cancer: if you wish, madam.
     Breast Cancer Res Treat, 114(1): 7-12. [Abstract] [Full-text]
160. Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series.
     Breast Cancer Res Treat, 114(1): 169-78. [Abstract] [Full-text]
161. Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts.
     Breast Cancer Res Treat, 114(1): 63-9. [Abstract] [Full-text]
162. Weight changes after adjuvant treatment in Korean women with early breast cancer.
     Breast Cancer Res Treat, 114(1): 147-53. [Abstract] [Full-text]
163. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.
     Breast Cancer Res Treat, 114(1): 31-8. [Abstract] [Full-text]
164. Nipple-sparing mastectomy: risk of nipple-areolar recurrences in a series of 579 cases.
     Breast Cancer Res Treat, 114(1): 97-101. [Abstract] [Full-text]
165. Functional identification of genes causing estrogen independence of human breast cancer cells.
     Breast Cancer Res Treat, 114(1): 23-30. [Abstract] [Full-text]
166. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
     Breast Cancer Res Treat, 114(1): 103-12. [Abstract] [Full-text]
167. Inhibition of NF-kappaB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate.
     Cancer Chemother Pharmacol, 63(4): 673-80. [Abstract] [Full-text]
168. Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?
     Cancer Chemother Pharmacol, 63(4): 627-33. [Abstract] [Full-text]
169. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells.
     BMC Cancer, 9: 3. [Abstract] [Full-text]
170. Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.
     Biochem Biophys Res Commun, 379(3): 696-701. [Abstract] [Full-text]
171. Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
     Biochem Biophys Res Commun, 379(3): 785-9. [Abstract] [Full-text]
172. Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: Application to pharmacokinetics in breast cancer and lupus nephritis patients.
     Chirality, 21(3): 383-9. [Abstract] [Full-text]
173. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer.
     JAMA, 301(4): 404-14. [Abstract] [Full-text]
174. The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma.
     BMC Cancer, 9: 18. [Abstract] [Full-text]
175. Prevalence, sources, and predictors of soy consumption in breast cancer.
     Nutr J, 8: 2. [Abstract] [Full-text]
176. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
     Oncogene, 28(4): 575-86. [Abstract] [Full-text]
177. Palladin contributes to invasive motility in human breast cancer cells.
     Oncogene, 28(4): 587-98. [Abstract] [Full-text]
178. Treating elderly patients with hormone sensitive breast cancer: what do the data show?
     Cancer Treat Rev, 35(1): 47-56. [Abstract] [Full-text]

© 2004-2010 Breast Cancer Research Today. All Rights Reserved.